Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
about
Ligand-based targeted therapy: a novel strategy for hepatocellular carcinomaPreparation, characterization, in vivo pharmacokinetics, and biodistribution of polymeric micellar dimethoxycurcumin for tumor targeting.GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.Self-Assembly Assisted Fabrication of Dextran-Based Nanohydrogels with Reduction-Cleavable Junctions for Applications as Efficient Drug Delivery Systems.Trigger responsive polymeric nanocarriers for cancer therapy.Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.Hyaluronic acid in digestive cancers.RGD peptide targeted lipid coated nanoparticles for combinatorial delivery of sorafenib and quercetin against hepatocellular carcinoma.New developments and clinical transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: reversing multidrug resistance, tumour-specific targetability and improved anticancer efficacy.Hyaluronic acid-based nano-sized drug carrier-containing Gellan gum microspheres as potential multifunctional embolic agent.Dual-Targeted Molecular Imaging of Cancer.Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics.Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
P2860
Q28068437-B37276D3-73BF-485C-873F-551CB6399987Q36160393-916A32B2-DA89-4E5A-9C00-2ACC2EFA66BDQ37344290-51E0D70E-11D3-4567-8507-A2572904DE2BQ37576006-8769A37F-F6EF-4667-B539-021CFCC5353FQ38556755-2734AC7F-DDD2-4813-9D20-43EAEEC8F19AQ38826497-578D25D3-38AF-4EB6-9534-F5EB94C6ACD9Q38930438-AA1C6A90-1509-494C-BB18-47BD85B38B69Q40688909-4CE4D6C1-4D01-48F4-91D2-E3B6395A1ED7Q46949800-1FBCD40F-CA0E-4437-9645-D4191538E1D8Q47715624-D2BA1998-76B6-499E-8AA5-07B34694896EQ48550017-99F2F4E0-9BA9-49B1-95B1-3E978540EF91Q50422486-CB824801-9F52-4EEF-9E64-E315D9C09751Q50914838-F32D2D8C-83F7-49C7-8652-4D1006453C4DQ53639202-8FD6A43A-5DA3-4B10-AFD8-0668112E413F
P2860
Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Hepatocellular carcinoma duall ...... lular delivery of doxorubicin.
@en
type
label
Hepatocellular carcinoma duall ...... lular delivery of doxorubicin.
@en
prefLabel
Hepatocellular carcinoma duall ...... lular delivery of doxorubicin.
@en
P2093
P1476
Hepatocellular carcinoma duall ...... lular delivery of doxorubicin.
@en
P2093
Danrong Hu
Jiasheng Tu
Nadia Bourkaib
P304
P356
10.1016/J.IJPHARM.2014.10.041
P407
P577
2014-10-22T00:00:00Z